STOCKS TELEGRAPH

Tag: NASDAQ:LPCN

  • Lipocine Inc. (LPCN) stock surged in the after-hours on Wednesday after a recent announcement

    Lipocine Inc. (LPCN) shares surged 11.63% in after-hours on Wednesday, July 14, 2021, and closed the trading at $1.44 per share. Earlier in the morning session on Wednesday, LPCN’s stock lost 2.27% to close Wednesday’s session at $1.29. LPCN shares have risen 4.88% over the last 12 months, and they have moved down 4.44% in the past week. Over the past three months, the stock has lost 12.24%, while over the past six months, it has shed 20.86%.

    Let’s have a brief look at its recent developments.

    Settlement With Clarus Therapeutics

    On July 14, 2021, Lipocine Inc entered into a global settlement and license agreement with Clarus Therapeutics Inc (Clarus) to resolve all outstanding claims in the ongoing intellectual property battle between the two companies as well as the ongoing interference proceeding between the two companies.

    Both companies agreed to dismiss the Lipocine Inc. v Clarus Therapeutics, Inc., No 19-cv-622 (WCB) litigation presently pending in the U.S. District Court for the District of Delaware and interference proceedings captioned Clarus Therapeutics, Inc. v. Lipocine Inc., Interference No. 106,128 presently pending in the U.S. Patent and Trademark. The terms of the settlement remain confidential.

    Participation in the recent health and investor conferences

    Lipocine Inc recently participated virtually at Ladenburg Thalmann Healthcare Conference, which held on July 13-14, 2021.

    Earlier, the company took part in The International Liver Congress™ in 2021, the annual meeting of the European Association for the Study of the Liver (EASL), Digital Event, which held on June 23-26, 2021.

    Lipocine was present at Raymond James Human Health Innovation Conference which held on June 21-23, 2021, and at Lytham Partners Summer 2021 Investor Conference which held on June 14-16, 2021.

    LPCN 1154 IND application cleared by FDA

    On June 14, 2021, the U.S. Food and Drug Administration (FDA) cleared Lipocine’s Investigational New Drug Application to initiate a Phase 2 study to evaluate the therapeutic potential of LPCN 1154, an oral neuro-steroid product candidate, for the treatment of postpartum depression in adults.

    Clarus Therapeutics won Patent Infringement Case against Lipocine

     

    On May 25, 2021, The U.S. District Court for the District of Delaware granted Clarus Therapeutics’ motion for summary judgment against remaining patents in a patent infringement case brought by Lipocine Inc regarding Clarus’s oral testosterone replacement product, Jatenzo.

    The statement gave Clarus an unequivocal win, Judge Bryson found all of the asserted Lipocine patents claims invalid.

    Conclusion

    The latest settlement with Clarus Therapeutics was the reason behind its gains in the after-hours on Wednesday because investors always take such news as a positive development. We can see LPCN to surge in the coming days.

  • Lipocine Inc. [LPCN] is a stock which investors cannot afford to ignore

    Lipocine Inc. (Nasdaq: LPCN), shares have changed -12.80% in price in a 5-day period, and -10.63% in the past three months. Shares of LPCN are up 5.15% YTD, with their twelve-month performance up 162.48%. In the last year, the lowest price was $53.15 and the highest was $138.79.

    Lipocine Inc. (Nasdaq: LPCN), is a clinical-stage biopharmaceutical company developing novel drug delivery technologies for metabolic and endocrine disorders. TLANDO, LPCN 1144, TLANDO XR, LPCN 1148 and LPCN 1107 are in Lipocine’s clinical development pipeline. The FDA has tentatively approved TLANDO, an oral prodrug of testosterone containing testosterone undecanoate, for the treatment of men who have deficiency of endogenous testosterone, also called hypogonadism.

    WHAT HAPPENED RECENTLY

    It was announced March 3, 2021 that Lipocine Inc. (Nasdaq: LPCN), the developer of TLANDO, will present their clinical data at the ENDO 2021 Conference, which is scheduled for March 20-23, 2021. For adult males with conditions associated with a lack of endogenous testosterone, called hypogonadism, TLANDO is an oral testosterone replacement therapy product candidate.

    Meanwhile,

    An analysis of the pharmaceutical industry shows that only a small percentage of Phase I products ever make it to the market. Typically, the percentage rises to 40% in Phase II and 70% in Phase III. Thus, a drug at Phase I is clearly a riskier investment than at Phase III. Market potentials can be determined using publicly available data on patient populations and current prices per patient/year. An analysis of competitor activity will demonstrate the number of companies conducting research on the same disease, and the level of their progress. The analysts claim that as a result, all major risks in a product development are quantifiable, such as clinical and competitor risk. It is possible to calculate the net present value or its net value to the company by adding up the risks.